CLS Q4: Paves the path for an exciting 2024 - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

CLS Q4: Paves the path for an exciting 2024 - Redeye

{newsItem.title}

Redeye provides an update in relation to CLS’ Q4 2023 report. Based on the report and the company’s business update event, we make some estimate changes that both positively and negatively affect our valuation. However, we include a future capital raising to our model, diluting our fair value range with a base case of SEK0.3 (0.4).

Länk till analysen i sin helhet: https://www.redeye.se/research/985949/cls-q4-paves-the-path-for-an-exciting-2024?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt